Oprimed Selected for the 2024 TIPS Program

Oprimed Selected for the 2024 TIPS Program

Oprimed Selected for the 2024 TIPS Program

Oprimed Selected for the 2024 TIPS Program

24. 12. 6.

24. 12. 6.

Oprimed Selected for the 2024 TIPS Program

Oprimed Selected for the 2024 TIPS Program

Oprimed Co., Ltd., a digital twin clinical simulation startup, was selected for the Deep Tech TIPS program by the Korean Ministry of SMEs and Startups, receiving up to KRW 1.7 billion to enhance its OPTIVIS technology and accelerate global expansion.

Oprimed Co., Ltd., a digital twin clinical simulation startup, was selected for the Deep Tech TIPS program by the Korean Ministry of SMEs and Startups, receiving up to KRW 1.7 billion to enhance its OPTIVIS technology and accelerate global expansion.

Oprimed Co., Ltd. is developing a technology that enhances clinical trial design and prediction accuracy through its AI-based human digital twin platform, OPTIVIS, and has been selected for the TIPS (Tech Incubator Program for Startups), securing up to KRW 1.5 billion in R&D funding along with additional support for business development and overseas marketing.

OPTIVIS maximizes clinical trial efficiency by generating AI-driven virtual patients tailored to individual profiles, helping pharmaceutical companies reduce the cost and duration of drug development.

Through this TIPS project, Oprimed plans to further advance its data analysis automation and segmentation capabilities, accelerating its expansion into global markets.

Oprimed Co., Ltd. is developing a technology that enhances clinical trial design and prediction accuracy through its AI-based human digital twin platform, OPTIVIS, and has been selected for the TIPS (Tech Incubator Program for Startups), securing up to KRW 1.5 billion in R&D funding along with additional support for business development and overseas marketing.

OPTIVIS maximizes clinical trial efficiency by generating AI-driven virtual patients tailored to individual profiles, helping pharmaceutical companies reduce the cost and duration of drug development.

Through this TIPS project, Oprimed plans to further advance its data analysis automation and segmentation capabilities, accelerating its expansion into global markets.

Oprimed Co., Ltd. is developing a technology that enhances clinical trial design and prediction accuracy through its AI-based human digital twin platform, OPTIVIS, and has been selected for the TIPS (Tech Incubator Program for Startups), securing up to KRW 1.5 billion in R&D funding along with additional support for business development and overseas marketing.

OPTIVIS maximizes clinical trial efficiency by generating AI-driven virtual patients tailored to individual profiles, helping pharmaceutical companies reduce the cost and duration of drug development.

Through this TIPS project, Oprimed plans to further advance its data analysis automation and segmentation capabilities, accelerating its expansion into global markets.

Oprimed Co., Ltd. is developing a technology that enhances clinical trial design and prediction accuracy through its AI-based human digital twin platform, OPTIVIS, and has been selected for the TIPS (Tech Incubator Program for Startups), securing up to KRW 1.5 billion in R&D funding along with additional support for business development and overseas marketing.

OPTIVIS maximizes clinical trial efficiency by generating AI-driven virtual patients tailored to individual profiles, helping pharmaceutical companies reduce the cost and duration of drug development.

Through this TIPS project, Oprimed plans to further advance its data analysis automation and segmentation capabilities, accelerating its expansion into global markets.

Oprimed Co., Ltd. is developing a technology that enhances clinical trial design and prediction accuracy through its AI-based human digital twin platform, OPTIVIS, and has been selected for the TIPS (Tech Incubator Program for Startups), securing up to KRW 1.5 billion in R&D funding along with additional support for business development and overseas marketing.

OPTIVIS maximizes clinical trial efficiency by generating AI-driven virtual patients tailored to individual profiles, helping pharmaceutical companies reduce the cost and duration of drug development.

Through this TIPS project, Oprimed plans to further advance its data analysis automation and segmentation capabilities, accelerating its expansion into global markets.

Oprimed Co., Ltd. is developing a technology that enhances clinical trial design and prediction accuracy through its AI-based human digital twin platform, OPTIVIS, and has been selected for the TIPS (Tech Incubator Program for Startups), securing up to KRW 1.5 billion in R&D funding along with additional support for business development and overseas marketing.

OPTIVIS maximizes clinical trial efficiency by generating AI-driven virtual patients tailored to individual profiles, helping pharmaceutical companies reduce the cost and duration of drug development.

Through this TIPS project, Oprimed plans to further advance its data analysis automation and segmentation capabilities, accelerating its expansion into global markets.

Connecting to

a Better Future

Meet OPRIMED today.

OPRIMED Inc.

CEO Suji Hong

Business Registration Number

277-87-02894

Headquarters (Ulsan)

Room 601, Ulsan Startup Hub,Jongha Innovation Center,

32, Bongwol-ro 38beon-gil,

Nam-gu, Ulsan, South Korea

info@oprimed.com

Big Data Lab (Suwon)

10th Floor, Room 1001,

Gwanggyo Central Business

Tower, 260 Changnyong-daero, Yeongtong-gu, Suwon,

Gyeonggi Province





© 2025 OPRIMED INC. (All Rights Reserved)

Connecting to

a Better Future

Meet OPRIMED today.

OPRIMED Inc.

CEO Suji Hong

Business Registration Number

277-87-02894

Headquarters (Ulsan)
Room 601, Ulsan Startup Hub,Jongha Innovation Center,

32, Bongwol-ro 38beon-gil,

Nam-gu, Ulsan, South Korea

info@oprimed.com

Big Data Lab (Suwon)
10th Floor, Room 1001,

Gwanggyo Central Business

Tower, 260 Changnyong-daero,
Yeongtong-gu, Suwon,

Gyeonggi Province







© 2025 OPRIMED Inc. (All Rights Reserved)

Connecting to

a Better Future

Meet OPRIMED today.

OPRIMED Inc.

CEO Suji Hong

Business Registration Number

277-87-02894

Headquarters (Ulsan)
Room 601, Ulsan Startup Hub,Jongha Innovation Center,

32, Bongwol-ro 38beon-gil,

Nam-gu, Ulsan, South Korea

info@oprimed.com

Big Data Lab (Suwon)
10th Floor, Room 1001,

Gwanggyo Central Business

Tower, 260 Changnyong-daero,
Yeongtong-gu, Suwon,

Gyeonggi Province







© 2025 OPRIMED Inc. (All Rights Reserved)

© 2025 OPRIMED Inc. (All Rights Reserved)

Connecting to

a Better Future

Meet OPRIMED

today.

OPRIMED Inc.

CEO Suji Hong

Business Registration Number

277-87-02894

Headquarters (Ulsan)

Room 601, Ulsan Startup Hub,

Jongha Innovation Center,

32, Bongwol-ro 38beon-gil,

Nam-gu, Ulsan, South Korea

Big Data Lab (Suwon)

10th Floor, Room 1001,

Gwanggyo Central Business Tower, 260 Changnyong-daero,

Yeongtong-gu, Suwon,

Gyeonggi Province

info@oprimed.com